---
document_datetime: 2025-11-21 14:50:35
document_pages: 6
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/neuraceq-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: neuraceq-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 15.2391206
conversion_datetime: 2025-12-29 22:11:54.204741
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

## Neuraceq

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

<!-- image -->

<div style=\"page-break-after: always\"></div>

| Application number                    | Scope                                                                                                                                                                                                                                                                                                                                                                                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Article 61(3) / EMA/N/0000307291      | - Notification acc. Article 61(3) - Accepted Update of the product information to replace the EXP formula 'ToC + 6h' with 'ToC + 6h (see outer label)' in section '3. Expiry date' of the minimum particulars to appear on small immediate packaging units (vial) in the labelling. Additionally, the MAH took the opportunity to introduce a minor typographical correction in the Lithuanian labelling. | 21/11/2025                          |                                             | Labelling                        |           |
| Variation type II / EMA/VR/0000227744 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of section 4.5 of the SmPC to reflect new preclinical data and editorial update of section 5.1. The Package Leaflet is also updated with discontinuation of the paper         | 24/07/2025                          |                                             | SmPC, Annex II and PL            |           |

<div style=\"page-break-after: always\"></div>

|                                       | copy SmPC. In addition, Annex IID is updated with deletion of additional risk minimisation measures. The RMP version 7.0 is agreed.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |            |                            |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------|
| Variation type IA / EMA/VR/0000280149 | This was an application for a group of variations. B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.a Replacement or addition of a site where batch control/testing takes place - Accepted B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.a Replacement or addition of a site where batch control/testing takes place - Accepted A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted | 23/06/2025 |            | Annex II, Labelling and PL |
| Variation type IB / EMA/VR/0000225729 | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 31/10/2024 | 13/01/2025 | Annex II, Labelling and    |

<div style=\"page-break-after: always\"></div>

| B.II.d.1 Change in the specification parameters and/or limits of the finished product - B.II.d.1.d Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter such as odour and taste or identification test for a colouring or flavouring material) - Accepted  B.I.a.1 Change in the manufacturer of a  starting material/reagent/intermediate used  in the manufacturing process of the active  substance or change in the manufacturer  (including where relevant quality control  testing sites) of the active substance, where  no Ph. Eur. Certificate of Suitability is part of  the approved dossier - B.I.a.1.z - Change in  the manufacturer of AS or of a starting  material/reagent/intermediate for AS - Other  variation - Accepted  B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.a Secondary packaging site - Accepted  B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.b Primary packaging site - Accepted  PL   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.f Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile medicinal products (including those that are aseptically manufactured) excluding biological/ immunological medicinal products - Accepted B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.a Replacement or addition of a site where batch control/testing takes place - Accepted B.II.b.2.c Replacement or addition of a manufacturer responsible for importation and/or batch release - B.II.b.2.c.2 Including batch control/testing - Accepted B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.c Other changes to a test procedure (including replacement or addition) for a reagent, which does not have a significant effect on the overall quality of the active substance - Accepted   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>